Standard BioTools Inc. (NASDAQ:LAB) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. reduced its holdings in Standard BioTools Inc. (NASDAQ:LAB) by 29.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 22,493 shares of the company’s stock after selling 9,604 shares during the period. Principal Financial Group Inc.’s holdings in Standard BioTools were worth $43,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of LAB. SG Americas Securities LLC acquired a new position in shares of Standard BioTools during the 1st quarter worth about $71,000. Vanguard Group Inc. raised its holdings in shares of Standard BioTools by 215.3% during the first quarter. Vanguard Group Inc. now owns 13,034,043 shares of the company’s stock valued at $35,322,000 after acquiring an additional 8,900,104 shares during the last quarter. CANADA LIFE ASSURANCE Co purchased a new position in shares of Standard BioTools in the first quarter valued at approximately $58,000. Shell Asset Management Co. acquired a new stake in shares of Standard BioTools in the first quarter worth approximately $39,000. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Standard BioTools by 157.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 68,869 shares of the company’s stock worth $187,000 after purchasing an additional 42,069 shares in the last quarter. 53.74% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, TD Cowen dropped their target price on shares of Standard BioTools from $2.75 to $2.50 and set a “buy” rating for the company in a report on Thursday, October 31st.

Standard BioTools Trading Up 5.6 %

LAB opened at $1.71 on Wednesday. The stock’s 50-day moving average price is $1.86 and its 200 day moving average price is $2.02. Standard BioTools Inc. has a 12-month low of $1.21 and a 12-month high of $3.04. The firm has a market cap of $636.56 million, a price-to-earnings ratio of -2.28 and a beta of 1.57.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.